Cantor Fitzgerald Forecasts Scholar Rock FY2025 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Scholar Rock in a research note issued to investors on Thursday, July 17th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($3.14) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Scholar Rock's FY2026 earnings at ($2.72) EPS.

Several other brokerages have also issued reports on SRRK. Lifesci Capital upgraded shares of Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Wedbush restated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, June 18th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Stock Performance

Shares of SRRK opened at $40.72 on Monday. Scholar Rock has a 12-month low of $6.76 and a 12-month high of $46.98. The company has a current ratio of 10.25, a quick ratio of 10.25 and a debt-to-equity ratio of 0.16. The company has a market cap of $3.87 billion, a PE ratio of -16.09 and a beta of 0.33. The stock has a 50-day moving average price of $33.76 and a 200-day moving average price of $35.00.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period in the prior year, the firm posted ($0.59) earnings per share.

Institutional Trading of Scholar Rock

A number of institutional investors have recently made changes to their positions in SRRK. CWM LLC boosted its holdings in shares of Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after purchasing an additional 602 shares during the period. Federated Hermes Inc. bought a new position in Scholar Rock during the 1st quarter valued at approximately $71,000. GF Fund Management CO. LTD. lifted its holdings in Scholar Rock by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock worth $77,000 after buying an additional 430 shares during the period. Strs Ohio bought a new stake in shares of Scholar Rock in the 1st quarter worth approximately $77,000. Finally, AlphaQuest LLC grew its position in shares of Scholar Rock by 490.7% in the 1st quarter. AlphaQuest LLC now owns 5,417 shares of the company's stock worth $174,000 after buying an additional 4,500 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company's stock.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Jeffrey S. Flier sold 20,316 shares of the company's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $32.24, for a total transaction of $654,987.84. Following the completion of the sale, the director directly owned 24,070 shares in the company, valued at $776,016.80. This represents a 45.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kristina Burow sold 5,400 shares of the business's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $160,488.00. Following the completion of the sale, the director directly owned 21,071 shares of the company's stock, valued at approximately $626,230.12. This trade represents a 20.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,654 shares of company stock worth $3,265,961 in the last 90 days. Corporate insiders own 13.30% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.